Cite

    Diamantopoulos, P. et al. (2021). The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. British journal of haematology. pp. 978-987. [Online].